No question that Vertex Pharmaceuticals ($VRTX) needs another hit to follow its new hepatitis C drug Incivek. But that's just one of the things on the to-do list for incoming CEO Jeffrey Leiden, who takes over for Matthew Emmens Feb. 1. FierceBiotech chatted with both men about the challenges. Interview